Rallybio Corp (RLYB): Price and Financial Metrics

Rallybio Corp (RLYB): $2.36

0.03 (+1.29%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add RLYB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#288 of 360

in industry

RLYB Price/Volume Stats

Current price $2.36 52-week high $9.88
Prev. close $2.33 52-week low $1.23
Day low $2.29 Volume 192,900
Day high $2.51 Avg. volume 274,581
50-day MA $1.90 Dividend yield N/A
200-day MA $4.17 Market Cap 89.19M

RLYB Stock Price Chart Interactive Chart >


Rallybio Corp (RLYB) Company Bio


Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of complement factor 5, or C5, for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. The company also has discovery-stage programs that are focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was incorporated in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporation operates as a subsidiary of Rallybio Holdings, LLC.


RLYB Latest News Stream


Event/Time News Detail
Loading, please wait...

RLYB Latest Social Stream


Loading social stream, please wait...

View Full RLYB Social Stream

Latest RLYB News From Around the Web

Below are the latest news stories about RALLYBIO CORP that investors may wish to consider to help them evaluate RLYB as an investment opportunity.

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

NEW HAVEN, Conn., December 20, 2023--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated diseases.

Yahoo | December 20, 2023

Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting

NEW HAVEN, Conn., December 09, 2023--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today presented details from the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study in a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting, in San Diego, California. The FNAIT natural h

Yahoo | December 9, 2023

Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

NEW HAVEN, Conn., November 28, 2023--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary data from the completed multiple dose cohort of the Phase 1 safety and pharmacokinetics (PK) study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia.

Yahoo | November 28, 2023

Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates

NEW HAVEN, Conn., November 09, 2023--Rallybio Corporation (Nasdaq: RLYB) today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent program and corporate developments.

Yahoo | November 9, 2023

Rallybio to Present at Upcoming Investor Conferences in November

NEW HAVEN, Conn., November 08, 2023--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences:

Yahoo | November 8, 2023

Read More 'RLYB' Stories Here

RLYB Price Returns

1-mo 80.15%
3-mo -10.61%
6-mo -56.54%
1-year -70.24%
3-year N/A
5-year N/A
YTD -1.26%
2023 -63.62%
2022 -31.13%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!